|
Alemtuzumab
resources
|
|
|
|
|
|
DRUG INFO
Alemtuzumab
Drug Name:
Alemtuzumab
Indication: For treatment of B-cell chronic lymphocytic leukemia
Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.
Mechanism Of Action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.
Drug Category: Antineoplastic Agents
Brand Names/Synonyms: Campath; Campath (ILEX Pharmaceuticals LP)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti-CD52 antibody
Chemical Formula: C6468H10066N1732O2005S40 >1CE1:L CAMPATH-1H:Light Chain 1 >1CE1:H CAMPATH-1H:Heavy Chain 2 >1CE1:L CAMPATH-1H:Light Chain 2
Half Life: ~288 hrs
Drug Type: Approved Drug
# Accession No: BIOD00109
CAS Registry Number: Not Available
|
|
|
|
|
|
Alemtuzumab News
(When available)
Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is ... Dec 12, 2005
PR Newswire UK (press release), According to interim results from the Phase II UKCLL02 trial, when administered subcutaneously (SC), MabCampath(R) (alemtuzumab) is both effective and well ...
New Study Reinforces Increased Life Expectancy with MabCampath(R) ... Dec 13, 2005
PR Newswire UK (press release), According to a study presented at the 47th Annual Meeting of the American Society of Hematology in Atlanta, Georgia, patients with B-cell Chronic Lymphocytic ...
Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is ... Dec 12, 2005
Biotech Intelligence (press release), 12/PRNewswire/ -- According to interim results from the Phase II UKCLL02 trial, when administered subcutaneously (SC), MabCampath(R) (alemtuzumab) is both ...
The Hypereosinophilic Syndromes Dec 27, 2005
Medscape (subscription) Newer therapies include imatinib as well as the possible future use of mepolizumab (a humanized monoclonal antibody against IL-5) and alemtuzumab (an anti-CD52 ...
Point Therapeutics Announces Positive Interim Results at American ... Dec 12, 2005
Business Wire (press release), Importantly, three of these five patients had not only failed fludarabine and rituximab, but had also failed prior alemtuzumab treatment--the only approved ...
(PRN) - Option Recognized as a Red Herring Small Cap 100 ... [+] Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is Effective and Safe for Patients Suffering from Fludarabine-Refractory CLL ... [+. ...
SUPG: Nipent Studies Presented at ASH Dec 9, 2005
PharmaLive.com (press release), 2. Abstract #5024 Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders. ...
(PRN) - Telekom Austria Selects Axiom Systems to Deploy Triple ... Dec 13, 2005
Bolsamania.com, ...(PRN) - New Study Reinforces Increased Life Expectancy with MabCampath(R) (alemtuzumab) for Patients with Advanced, Pretreated B-cell Chronic Lymphocytic ...
Enter symbol(s) Dec 9, 2005
Yahoo! News (press release) ...of Previously Untreated or Treated Bulky Stage II or Stage III or IV, Low-Grade B-Cell NHL 2. Abstract #5024 Combined Therapy with Alemtuzumab and Pentostatin ...
Genzyme names new head of product development for Campath Jan 12, 2006
San Antonio Business Journal, ILEX developed Campath, the only monoclonal antibody approved by the Food and Drug Administration for the treatment of patients with B-cell chronic lymphocytic ...
Genzyme Names New Head of Product Development for Campath and ... Jan 13, 2006
Financial News USA (press release), FNWU) Genzyme Corp. (Nasdaq:GENZ) promoted Terry Murdock to lead product development of the oncology drug Campath. Murdock is the ...
Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue Jan 9, 2006
MSN Money Oncology revenue includes profits and royalties from Campath(R) (alemtuzumab for injection), which is marketed by Schering AG and its US affiliate Berlex ...
GENZYME: Pipeline Highlights Jan 12, 2006
Webbolt Business News (subscription), Genzyme and Schering AG Germany plan to initiate a Phase 3 clinical trial in the first half of this year evaluating Campath for the treatment of multiple ...
GX15-070 Active in Refractory CLL Jan 10, 2006
Cancer Consultants (press release), ...activity in patients with chronic lymphocytic leukemia (CLL) who have stopped responding to standard therapies including chemotherapy, Rituxan®, and Campath ...
Small Molecule Bcl-2 Protein Inhibitor, GX15-070, Active for ... Jan 12, 2006
Cancer Consultants (press release), The current study enrolled 25 patients with CLL refractory to fludarabine, alkylators and to Rituxan® and 40% had received a Campath® (lemtuzumab). ...
Early numbers from Genzyme show 24% revenue rise Jan 9, 2006
Boston Business Journal, ...its $1 billion purchase of Ilex Oncology Inc., pursued in large part to tap into that company's cancer drugs now under development or like Campath, for sale. ...
New Study Reinforces Increased Life Expectancy with MabCampath(R) ... Dec 13, 2005
PR Newswire UK (press release), MabCampath, also marketed as Campath(R) in the United States, is the first and only humanized monoclonal antibody approved for CLL and the first drug with ...
|
|
|
